Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 4Phase 3 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Active not recruiting 12Recruiting 9Completed 7Unknown 3Not yet recruiting 3Terminated 2

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 3Salivary Gland Neoplasms 1Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Female 1Biochemically Recurrent Prostate Cancer 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Completed × darolutamide × Clear all
NCT04925648 2026-04-23

PICASSO

St Vincent's Hospital, Sydney

Phase 2 Completed
4 enrolled
Genitourinary

Prostatic Neoplasms

NCT05694819 2026-04-08

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

National Cancer Center Hospital East

Phase 2 Completed
57 enrolled
Head & Neck

Salivary Gland Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT05526248 2026-03-11

ARAMON

Bayer

Phase 2 Completed
28 enrolled 14 charts
Genitourinary

Biochemically Recurrent Prostate Cancer

NCT05171387 2025-06-22

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Bayer

Phase 2 Completed
78 enrolled
Genitourinary

Prostatic Neoplasms

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
250 enrolled
Tumor-Agnostic

Neoplasms

NCT03383679 2022-11-21

START

UNICANCER

Phase 2 Completed
94 enrolled
Breast

Breast Cancer Female

NCT01429064 2017-02-20

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Orion Corporation, Orion Pharma

Phase 2 Completed
76 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡